News | August 13, 2014

Fusion Antibodies And C-Term Diagnostics Develop Novel In Vitro Diagnostic Products


C-Term and Fusion Antibodies have been working together for more than two years and have successfully developed highly specific antibodies against the signal transduction region of tissue factor for application in various immunoassay configurations. The companies are today announcing a significant breakthrough for a difficult to produce diagnostic antibody.

Belfast, UK (PRWEB UK) - C-Term Diagnostics is a private UK-based immunodiagnostic company focused on the development of novel in vitro diagnostic products for cancer and other diseases. The company is developing clinical laboratory kits and point of care rapid immunodiagnostic tests for population screening, monitoring therapy, and detection of recurrence of various cancers.

C-Term have stated that they are delighted to be working with Fusion Antibodies and that Fusion has been a most enthusiastic and helpful partner. The Fusion Antibodies team has provided critical polyclonal and monoclonal antibodies that have successfully been applied in C-Term's diagnostic kits. Fusion and C-Term have now jointly developed a difficult-to-produce genetically engineered antibody which will allow quantification of a specific epitope on tissue factor. "We are very confident that Fusion Antibodies will provide a high-quality genetically engineered antibody that has proved to be difficult to obtain through standard methods," says Dr. Robert Greenfield, CSO and co-founder of C-Term Diagnostics.

At the time of writing, successful proof of principle studies have already been completed and C-Term Diagnostics expect to have specific clinical trial work underway in the UK and beyond later this year. It is currently envisioned that the first diagnostic kits will be available in 2015.

C-Term Diagnostics' ground-breaking work with Fusion is planned to continue for some time with multiple connected programmes on the horizon.

About C-Term Diagnostics 
C-Term Diagnostics (Registered in England 6730705) is a private biotechnology company focused on the development of novel in vitro diagnostic products for cancer and other diseases.

About Fusion Antibodies 
Fusion Antibodies; a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies and Antibody Engineering Projects. With 12+ years of experience in the medical research industry, including two antibodies in clinical and pre-clinical trials, Fusion Antibodies have extensive experience in accelerating therapeutic drug research towards the clinic.

Fusion Antibodies has the knowledge and expertise to build and deliver a bespoke package of the services you need to achieve outstanding results. They provide Royalty Free Antibody Humanization of Monoclonal Antibodies and using their next generation in silico CDRx™ technology, they have modernized the traditional CDR grafting technique. Fully humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success.

Visit their website at to find our more.


View original release here: